Newsfeed

Selexipag meets primary endpoint in pivotal Phase III GRIPHON outcome study in patients with pulmonary arterial hypertension
ALLSCHWIL, SWITZERLAND - 16 June 2014 - Actelion Ltd (six:ATLN) today announced the top-line results of the pivotal Phase III GRIPHON study in 1,156 patients with pulmonary arterial hypertension (PAH) with selexipag, the first selective oral prostacyclin IP receptor agonist. Initial analysis shows that the event-driven outcome study has met its primary efficacy endpoint with high statistical significance. Selexipag decreased the risk of a morb…
Bayer Tests Riociguat to Treat Symptomatic Pulmonary Hypertension
Bayer HealthCare recently announced it will test the efficacy and safety of the drug Riociguat in patients with symptomatic pulmonary hypertension (PH) associated with idiopathic interstitial pneumonias (IIP). The study will take place at more than 50 sites in 11 countries and will include about 120 patients. Designed as signal-generating, the trial intends to improve knowledge about the disease and the drug’s effect on it. The RISE-IIP is a ran…
Reata Enrolls First Patient In Promising, New Pulmonary Arterial Hypertension Trial
Irving-based Reata Pharmaceuticals, a privately held company aiming to translate the company’s groundbreaking research into new therapies, has enrolled the first patient in a Phase 2 dose-ranging study that will examine the safety, tolerability, and efficacy of bardoxolone methyl in patients with pulmonary arterial hypertension (PAH). Pulmonary hypertension involves high blood pressure in the arteries of the lungs. The American Lung Association …
Bayer Trial Will Evaluate Riociguat in New Indication
Bayer HealthCare announced the start of a randomized, double-blind, placebo-controlled Phase 2b study. The RISE-IIP study (Riociguat in Patients with Symptomatic Pulmonary HypErtension associated with Idiopathic Interstitial Pneumonias) is designed to investigate the efficacy and safety of riociguat in patients with symptomatic pulmonary hypertension (PH) associated with idiopathic interstitial pneumonia (IIP). Pulmonary hypertension is a co-…
Supernus Receives $2 Million for United Therapeutics’ Launch of Orenitram
United Therapeutics Corporation paid Supernus Pharmaceuticals a $2 million milestone payment for the launch of United’s Orenitram Extended-Release Tablets for the treatment of pulmonary arterial hypertension (PAH) in the United States. A form of pulmonary hypertension, PAH is caused by the abnormal functioning of pulmonary artetires, which carry blood from the heart to the lungs. Although it has no cure, there are several treatment options, all …
Poorer Patients Present with More Advanced Pulmonary Hypertension
ATS 2014, SAN DIEGO ─ Pulmonary hypertension patients from lower socioeconomic groups present for initial evaluation at a more advanced disease state than those from higher income groups, according to a new study presented at the 2014 American Thoracic Society International Conference. "Lower socioeconomic status is associated with reduced access to health care and negative effects on health status, but data on its effects on the care of patie…
Pickering family raises awareness of rare lung disease
PICKERING -- A Pickering family is trying to raise awareness of pulmonary hypertension, a rare and potentially fatal lung disease. Isabelle Platnar, 8, was diagnosed with the disease at nine months old and requires supplementary oxygen at all times. When Isabelle Platnar rides her bike, her mom has to run behind her with an oxygen tank. The local eight-year-old has struggled with a rare lung disease since she was a baby and must been hooked up…
Higher BMI is associated with lower mortality risk in patients with severe PH
In patients with congestive heart failure, obesity and a larger waist size have paradoxically been associated with a better prognosis in the prior investigations. This effect, known as the obesity paradox phenomenon, is now being demonstrated in patients with severe pulmonary hypertension. "Obesity-related illnesses, particularly obesity hypoventilation syndrome and sleep apnea, may play a role in the development of pulmonary hypertension, …
Patients with low pulmonary vascular resistance may benefit from complex procedure for PH
Patients with chronic pulmonary thromboembolic disease may benefit from pulmonary thromboendarterectomy (PTE), even if the patients don't have severe pulmonary hypertension, according to University of California, San Diego, researchers. The study was presented at the 2014 American Thoracic Society International Conference. UCSD pioneered PTE in the 1970s for patients who suffered from chronic thromboembolic pulmonary hypertension (CTEPH). …
Underdiagnosed lung disease leaves victims short of breath
It can be an invisible killer. A rare and potentially fatal lung disease sharing symptoms with so many common ailments, it can often fool the very medical specialists who are trained to recognize it. There is no cure, and in the most severe cases -- if left undetected and untreated -- the patient could be dead within an average of two to three years. About 5,000 Canadians have already been diagnosed with pulmonary hypertension (PH) -- wh…
Recent News

Subscribe

Get the latest on PH treatments, community events and more when you subscribe to our newsletter

ImagineCan_Accreditation_Trustmark_ENGFR_WHT-FNL_white.png